• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NxStage Medical urges Medicare to pony up for home hemodialysis

NxStage Medical urges Medicare to pony up for home hemodialysis

September 10, 2013 By Ingrid Mezo

NxStage Medical urges Medicare to pony up for home hemodialysis

Home hemodialysis system maker NxStage Medical (NSDQ:NXTM) urged the Centers for Medicare & Medicaid Services to increase coverage for home hemodialysis training for patients with end-stage renal disease.

Lawrence, Mass.-based NxStage was responding to a CMS Proposed Rule for Changes to the End-Stage Renal Disease Prospective Payment System for 2014, in which the agency put forward an add-on payment of $33.44 per required training session.

The company argued that the increase is inadequate, because an actual home hemodialysis training session runs to $250-$260, based on Medicare’s own updated cost report data.

"It is no surprise, then, that most centers don’t offer HHD, that so few patients know it is a real option for them, that the percentage of patients on HHD is so vastly different than what physicians and nurses say they would choose for themselves," NxStage said.

Its System One device is an FDA-home-use-cleared portable hemodialysis system that can be combined with the company’s Pureflow SL dialysis preparation system to turn tap water into dialysis fluid. Under physician guidance, patients can use System One with their trained partners as needed in any setting, according to the company.

NxStage cited a number of reasons Medicare should boost the add-on payment for HHD training, apart from the discrepancy between the proposed increase and the actual cost of training.

Clinical data supports superior patient outcomes with HHD, including more frequent hemodialysis when patients can do it at home vs. at a conventional dialysis center, the company said.

In 3rd-party surveys, healthcare professionals said they would choose HHD most often for themselves if they had end-stage renal disease, in sharp contrast "with the small percentage of beneficiaries with access to HHD today," NxStage noted.

And Congress has ordered Medicare to develop policies to encourage more patients to be rehabilitated and treated in the home setting, according to the company.

"Given the clear and compelling benefits of home hemodialysis and the decades-old Congressional intent to encourage home dialysis and rehabilitation, it is essential that CMS update its policies for training payment to ensure beneficiary access to this modality," NxStage Medical President Joe Turk said in prepared remarks. "It is a disservice to patients to allow this situation to remain unresolved."

NxStage Medical founder & CEO Jeff Burbank told MassDevice.com earlier this year that essentially all private payers have already moved to "usual and customary payment" for NxStage therapy, but noted that "some work" with CMS is in order.

Filed Under: Dialysis, Medicare, News Well Tagged With: Centers for Medicare and Medicaid Services (CMS), Dialysis, NxStage Medical Inc.

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy